These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 33634418)

  • 41. Polycystic ovary syndrome and breast cancer subtypes: a Mendelian randomization study.
    Zhu T; Cui J; Goodarzi MO
    Am J Obstet Gynecol; 2021 Jul; 225(1):99-101. PubMed ID: 33771497
    [No Abstract]   [Full Text] [Related]  

  • 42. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer.
    Barrow TM; Barault L; Ellsworth RE; Harris HR; Binder AM; Valente AL; Shriver CD; Michels KB
    Int J Cancer; 2015 Aug; 137(3):537-47. PubMed ID: 25560175
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triple negative breast cancer: from molecular portrait to therapeutic intervention.
    Carotenuto P; Roma C; Rachiglio AM; Botti G; D'Alessio A; Normanno N
    Crit Rev Eukaryot Gene Expr; 2010; 20(1):17-34. PubMed ID: 20528735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.
    Omarini C; Bettelli S; Caprera C; Manfredini S; Barbolini M; Moscetti L; Isca C; Toss A; Barbieri E; Cortesi L; Kaleci S; Maiorana A; Tazzioli G; Cascinu S; Piacentini F
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):821-828. PubMed ID: 30603906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
    van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
    Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Triple-negative breast cancer: unique biology and its management.
    Maegawa RO; Tang SC
    Cancer Invest; 2010 Oct; 28(8):878-83. PubMed ID: 20839950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.
    Keshgegian AA
    Breast Cancer Res Treat; 1995 Aug; 35(2):201-10. PubMed ID: 7647342
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
    Greenberg S; Rugo HS
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S20-9. PubMed ID: 20805062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases.
    Yamanouchi K; Kuba S; Eguchi S
    Surg Today; 2020 Jul; 50(7):657-663. PubMed ID: 31190183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. P53, c-erbB-2 expression and steroid hormone receptors in breast carcinoma: correlations with histopathological parameters.
    Kilinç N; Yaldiz M
    Eur J Gynaecol Oncol; 2004; 25(5):606-10. PubMed ID: 15493177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy.
    Timmer M; Werner JM; Röhn G; Ortmann M; Blau T; Cramer C; Stavrinou P; Krischek B; Mallman P; Goldbrunner R
    Anticancer Res; 2017 Sep; 37(9):4859-4865. PubMed ID: 28870906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.
    Bieche I; Parfait B; Le Doussal V; Olivi M; Rio MC; Lidereau R; Vidaud M
    Cancer Res; 2001 Feb; 61(4):1652-8. PubMed ID: 11245479
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Discordance of Estrogen Receptor,Progesterone Receptor,Cerb-B2,Ki-67 Index and P53 Expressions between Primary and Recurrent or Metastatic Sites in Breast Cancer Patients].
    Peng L; Lin JZ; Zhao DC; Zhang YN; Mao F; Sun Q
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Oct; 41(5):673-677. PubMed ID: 31699199
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of Hormone Receptor Status on Spinal Metastatic Lesions in Patients with Breast Cancer.
    Lin J; Goldstein L; Nesbit A; Chen MY
    World Neurosurg; 2016 Jan; 85():42-8. PubMed ID: 26260940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification.
    Dong XF; Wang Y; Huang BF; Hu GN; Shao JK; Wang Q; Tang CH; Wang CQ
    Biomed Res Int; 2020; 2020():8823270. PubMed ID: 33134390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.
    Tang P; Wang J; Hicks DG; Wang X; Schiffhauer L; McMahon L; Yang Q; Shayne M; Huston A; Skinner KA; Griggs J; Lyman G
    Cancer Invest; 2010 Nov; 28(9):978-82. PubMed ID: 20690804
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.